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Abstract 
Evidence of an association between  early pregnancy exposure to Selective Serotonin 
Reuptake Inhibitors (SSRI) and congenital heart defects (CHD) has contributed to 
recommendations to weigh benefits and risks carefully. The objective of this study was to 
determine the specificity of association between first trimester exposure to SSRIs and specific 
CHD and other congenital anomalies (CA) associated with SSRI exposure in the literature 
(signals). A population-based case-malformed control study was conducted in 12 EUROCAT 
CA registries covering 2.1 million births 1995-2009 including livebirths, fetal deaths from 20 
weeks gestation and terminations of pregnancy for fetal anomaly. Babies/fetuses with specific 
CHD (n=12,876) and non-CHD signal CA (n=13,024), were compared with malformed 
controls whose diagnosed CA have not been associated with SSRI in the literature 
(n=17,083). SSRI exposure in first trimester pregnancy was associated with CHD overall 
(OR adjusted for registry 1.41, 95% CI 1.07-1.86, fluoxetine adjOR 1.43 95% CI 0.85-2.40, 
paroxetine adjOR 1.53, 95% CI 0.91-2.58) and with severe CHD (adjOR 1.56, 95% CI 1.02-
2.39), particularly Tetralogy of Fallot (adjOR 3.16, 95% CI 1.52-6.58) and Ebstein’s anomaly 
(adjOR 8.23, 95% CI 2.94-23.16). Significant associations with SSRI exposure were also 
found for anorectal atresia/stenosis (adjOR 2.46, 95% CI 1.06-5.68), gastroschisis (adjOR 
2.42, 95% CI 1.10-5.29), renal dysplasia (adjOR 3.01, 95% CI 1.61-5.61), and clubfoot 
(adjOR 2.41, 95% CI 1.59-3.65). These data support a teratogenic effect of SSRIs specific to 
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Introduction 
In Europe, between 3% and 11% of women have been estimated to have major depression in 
any one year [1-4]. Untreated depression in pregnancy impacts negatively on both the mother 
and the developing fetus, increasing the risk of premature delivery, low birth weight, small 
for gestational age and child developmental outcomes [5-6]. Pharmacotherapy is a popular 
treatment approach but the safety in pregnancy of most antidepressant medications is 
uncertain [7]. Therefore, guidelines recommend that pharmacotherapy should be avoided if 
possible in pregnancy in favour of non-pharmaceutical treatments except in the case of severe 
depression where benefits outweigh risks [8]. However, the critical period of organogenesis is 
early in pregnancy and pregnancies may be inadvertently exposed to antidepressant 
medication before women become aware they are pregnant, or there may not be sufficient 
time to change medication or treatment approach for women receiving treatment for 
depressive disorders who become pregnant. 
 
 
Antidepressant use in first trimester pregnancy has been estimated at 2.0-10.0% [9-14]. 
Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants are widely prescribed for 
treating major depression, including in pregnancy [13-16]. Prior to 2005, SSRIs were 
regarded to be safe in pregnancy, based mostly on prospective cohort studies with limited 
sample sizes [17-21]. Thereafter, starting with paroxetine [22], the SSRIs have come under 
scrutiny particularly in relation to congenital heart defects (CHD) [22-37]. Although not all 
studies have supported this association [38-45], meta-analyses have found positive overall 
evidence [46-50]. Some non-CHD congenital anomalies have also been linked to SSRI 
exposure in first trimester pregnancy [24, 29, 32, 34-35] although this literature is much 
smaller.  Inconsistencies in the literature can be expected due to different sources of bias, for 
4 
SSRI use in first trimester pregnancy and risk of congenital anomalies 
      Wemakor 
example the non-inclusion of terminations of pregnancy for fetal anomaly in many studies, 
different levels of accuracy in recording the diagnosis of CHD and other CA, use of different 
exposure window definitions [51] and small study population sizes which have meant that 
statistically significant risks appear to relate to the more common congenital anomalies (such 
as septal heart defects) or the more commonly used SSRIs. 
 
The biologic plausibility of a teratogenic effect of SSRIs in humans is based on studies of 
drug and metabolite levels in amniotic fluid and cord blood combined with evidence from 
animal studies [52]. Most SSRIs have a short half-life (approximately 1 day). Fluoxetine has 
a half-life of approximately 1-4 days and its metabolite norfluoxetine a half-life of 7-15 days 
[53].  Serotonin acts as an important signalling molecule in progenitor heart cells during the 
establishment of laterality, formation of the outflow tract, myocardial cell differentiation, and 
septation of the heart chambers [54] and abnormal levels during these critical periods e.g., 
through the activity of serotonin reuptake inhibitors, has been shown to lead to faulty 
morphogenesis in animal models [55-56].  
 
There remains, however, some controversy about the nature of the causal association in 
human epidemiological studies. It has been suggested that the apparent excess risk of less 
severe CHDs might reflect ascertainment bias due to greater likelihood of exposed babies 
receiving special neonatal care [48, 57-58]. Other studies have focused on confounding by 
indication or co-exposures including co-medications [23, 33, 59] finding evidence of 
attenuation of CHD risk.  
 
European Surveillance of Congenital Anomalies (EUROCAT) is a large congenital anomaly 
surveillance system [60] with a central database which has previously been used to study 
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risks of antiepileptic drug exposure [61]. Using the considerable statistical power provided, 
we examined the specificity of association between first trimester exposure to SSRIs and 
specific CHD and non-CHD anomaly subgroups. 
 
Materials and Methods 
Study design 
Case-malformed control study based on EUROCAT population-based congenital anomaly 
registries. Cases were babies with CHD, or with congenital anomalies other than CHD 
identified as significantly associated with SSRI exposure (“signals”) in at least one previous 
study. Controls were all other registrations. Genetic conditions were excluded from both 
cases and controls. 
 
Setting and Data Source 
EUROCAT registries were included if they had a recorded antidepressant exposure of at least 
3 per 1000 and at least 5 exposed registrations in designated 5 year periods: 1995-1999, 
2000-2004, 2005-2009. 12 registries in 12 European countries were included for all or part of 
1995-2009 (Table 1). The data from Northern Netherlands registry 1997-2006 have been 
previously published limited to paroxetine use [36]. The 12 registries registered 70,117 
babies/fetuses with congenital anomaly from a population of 2,177,977 births.  
Data were extracted from the central database of EUROCAT [60]. EUROCAT registries 
collect data on live births, stillbirths and late fetal deaths from 20 weeks gestation, and 
terminations of pregnancy for fetal anomaly (TOPFAs). Registries use multiple sources of 
information: maternity, neonatal, and paediatric records; fetal medicine, cytogenetic, 
pathology, and medical genetics records; paediatric cardiology services; and hospital 
discharge and child health records [62]. Eleven of the 12 registries register children with 
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congenital anomalies up to age one year or more.  A registrant can have up to 8 
malformations and one syndrome recorded. Congenital anomalies are coded to the 
International Classification of Diseases (ICD) version 9 or 10 with 1-digit BPA extension. 
These codes are classified into the standard EUROCAT malformation subgroups [63] (see 
Appendix). The severe CHD subgroup as defined by EUROCAT included all CHD 
subgroups with higher perinatal mortality (see Appendix) [64].  Babies/fetuses with only 
congenital anomalies categorised as minor according to EUROCAT definitions were 
excluded [63].  
 
Cases and controls 
Cases and controls were defined as livebirths, fetal deaths from 20 weeks, and terminations of 
pregnancy for fetal anomaly following prenatal diagnosis with non-genetic major CA. 7,813 
genetic registrations (chromosomal or single gene disorders) identified using the EUROCAT 
multiple malformation algorithm [65] were excluded as having a different preconceptional 
aetiology [66-67].  201 cases/controls with teratogenic syndromes were also excluded as of 
known cause. To avoid terminological confusion, we refer to any baby with congenital 
anomaly as a “registration”, covering both cases and controls and excluded babies.   
 
Cases of CHD: ICD codes Q20-26 (ICD10) and 745, 746, and 7470 to 7474 (ICD9-BPA), 
with or without extra-cardiac anomalies. Excluded from CHD were preterm deliveries (<37 
weeks) with only patent ductus arteriosus (Q250 or 7470), and all cases with only patent 
foramen ovale (Q2111) [62]. CHDs were classified into EUROCAT CHD subgroups [63] 
(see Appendix).  
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Cases of non-CHD “signals”:  Cases were 13 standard EUROCAT congenital anomaly 
subgroups (and organ system subgroups including those anomalies) which had shown 
statistically significant associations with one or more SSRI types in the literature (accessed 
via Pubmed and Embase up to June 2012) [24, 29, 32, 34-35]: 
Neural tube defects – paroxetine [35] 
anencephaly (part of neural tube defects) – SSRI, paroxetine [34]  
eye defects - paroxetine [24] 
ear/face/neck defects – fluoxetine [32] 
respiratory defects – sertraline [32] 
digestive system defects – fluoxetine [32] 
anorectal atresia and stenosis (part of digestive system) - sertraline [35]  
gastroschisis – paroxetine [34] 
omphalocele – SSRI, paroxetine, sertraline [34-35] 
renal dysplasia – SSRI [29, 32] 
hypospadias – paroxetine [29]  
limb reduction – sertraline [35]  
lower limb reduction (part of limb reduction) – SSRI [32] 
clubfoot – SSRI, paroxetine [35] 
craniosynostosis [34] 
Cases where any of the above were associated with CHD were analysed only as CHD cases.  
 
Controls. Controls were the remaining congenital anomaly registrations, after excluding all 
registrations with CHD or with a non-CHD “signal” congenital anomaly subgroup.  
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An exploratory analysis was conducted within the control group to determine whether any of 
the component anomalies were more commonly exposed to SSRI than other controls, 
adjusting odds ratios for registry. 
 
Exposure ascertainment 
For the most part, our medication exposure information came from maternal 
medical/midwifery notes, created prospectively [68]. Other additional data sources include 
paediatrician records (postnatal), medical geneticist records (postnatal), GP records of mother 
(prenatal), and maternal interviews (postnatal) (see Table1). One registry accesses a 
prescription database as its primary source and verifies use of prescribed medications through 
postnatal telephone interviews with the mothers. Data sources per registry are shown in Table 
1. Data sources were unbiased with respect to case/control status. Medication exposure was 
ascertained similarly for all types of pregnancy outcomes, except for one registry which did 
not obtain medication data for TOPFA (TOPFA for that registry were excluded from the 
dataset). Drug data are coded to the Anatomical Therapeutic Chemical (ATC) code [69]. 
Maternal illness before and during pregnancy is coded to ICD codes (ICD-9 or ICD-10). 
 
Exposure was defined as use of SSRI (ATC N06AB) without use of any other type of 
antidepressant. The first trimester of pregnancy was defined as the period from the first day 
of the last menstrual period up to the 12th week of gestation [63]. Women were excluded 
from the dataset if they took non-SSRI antidepressants (n=121) or unspecified 
antidepressants (n=39), and for the specific SSRI analyses, if they took more than one 
specific SSRI (n=1, citalopram + fluoxetine). Women were considered unexposed if the 
registry did not record use of any antidepressants in first trimester pregnancy. When using 
maternity records to ascertain medication usage, it is not always possible to distinguish no 
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usage of the medication from no reported usage - unknown medication use mainly indicated 
that the sources of medication information for the case were not available to the register, 
while no exposure indicated that the usual sources had been consulted but no exposure was 
recorded. Two registries (Antwerp and Tuscany) did not distinguish these two situations, and 
all of their cases without recorded exposure were considered unexposed. Six SSRI 
antidepressants were recorded: Fluoxetine (N06AB03), Citalopram (N06AB04), Paroxetine 
(N06AB05), Sertraline (N06AB06), Fluvoxamine (N06AB08), and Escitalopram 
(N06AB10). All were analysed individually except Fluvoxamine to which only six women 
were exposed. Where a significant association was found, exposed cases were checked with 
registries to verify first trimester exposure and drug type, and these case lists were also 
examined for evidence that co-exposure to other medications might constitute a significant 
source of confounding. The Atrial Septal Defect (ASD) cases exposed to SSRIs were in 
addition checked with the registries to determine whether they had been infants in specialist 
neonatal care who may have been examined more intensively, which could lead to diagnostic 
bias. 
 
To avoid misclassification of antidepressant exposure status, women with drug use unknown 
or missing (n=17,869, including all TOPFA from one of the registries) or those with a record 
of depression diagnosis with no record of antidepressant use (n=20) were excluded. To avoid 
confounding by co-exposure to identifiable teratogenic medications/condition, cases/controls 
were excluded if they had a record of exposure to antiepileptic medication (n=374), or 
antidiabetic medication/diabetes (n= 697), or they had teratogenic syndromes (n=201).  
 
After all exclusions, the study was based on the remaining 42,983 registrations. 
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Statistical analysis  
Logistic regression analysis was used to estimate Odds Ratios and 95% confidence intervals 
using Stata version 9.0 (Statacorp LP, College Station, TX, USA). Analysis was limited to 
congenital anomaly subgroups with at least 3 exposed cases as it was considered that odds 
ratios based on 1 or 2 cases could not be meaningfully interpreted. In cases where a 
statistically significant association was detected between SSRI (combined) and any 
congenital anomaly subgroup, results for specific SSRIs are presented even when the number 
of exposed cases was less than 3 to facilitate assessment of specificity of association between 
specific SSRIs and specific congenital anomalies. Analyses were adjusted for registry in 
order to adjust for confounding that may arise if registries differ in both exposure and 
outcome prevalences. As recommended for observational epidemiological studies, no 
statistical adjustment was performed for multiple testing [70], but design and interpretation 
took into account presence of a prior hypothesis.  
 
Ethics approval: EUROCAT has approval from the University of Ulster Research Ethics 
Committee. Additionally, all registries have ethical approval appropriate to their national and 
local ethics guidelines.  
 
Results 
A total of 42,983 non-genetic congenital anomaly registrations consisting of 12,876 with 
CHD, 13,024 with one or more of the 15 “signal” subgroups, and 17,083 controls were 
included in the analysis. Exposure to SSRIs in first trimester pregnancy among all 
registrations was 0.76% (328/42,983) (Table 1); 0.68%,and 0.66% of the CA registrations 
were exposed to SSRI in 1995-1999 and 2000-2004 respectively with the exposure increasing 
to 0.90% 2005-2009 (χ2=7.65, df=2, p = 0.022). By type of birth, 0.76% of livebirths, 0.79% 
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of TOPFA and 0.87% of stillbirths were exposed to SSRI (χ2=0.11, df=2, p = 0.945). 14.6% 
of the women who had SSRI prescriptions also had prescriptions for psycholeptic 
medications. 
 
Among the controls, 99 registrations were exposed to SSRIs, of which 27 were to fluoxetine, 
27 to paroxetine, 20 to citalopram, 14 to sertraline, 9 to escitalopram and one to fluvoxamine. 
 
Congenital Heart Defects 
SSRI (combined) exposure was significantly associated with CHD (OR 1.41, 95% CI 1.07-
1.86, Table 2); the association was similar or slightly stronger for severe CHD (OR 1.56, 
95% CI 1.02-2.39, Table 2) while the association with the main other CHD group, septal 
defects, was slightly lower and of borderline statistical significance (OR 1.36, 95% CI 0.99-
1.87, Table 2). Assessing specific SSRIs for CHD combined, the raised odds does not appear 
to be specific to any one SSRI – odds ratios were between 1.43 and 1.53 with overlapping 
confidence intervals for the four most common SSRIs, and a lower OR with a wide 
confidence interval was found only for escitalopram (OR 1.10, 95% CI 0.41-2.95). Assessing 
specificity of association for specific SSRIs and severe CHD also did not reveal raised odds 
limited to any one SSRI (Table 2). 
 
Statistically significant associations were detected between SSRI and Tetralogy of Fallot 
(TOF) (OR 3.16, 95% CI 1.52-6.58, 8 exposed cases, Table 2). The TOF association was not 
limited to any one specific SSRI (Table 2). 
 
The strongest association with SSRI exposure was for Ebstein’s anomaly (OR 8.23, 95% CI 
2.92-23.16), with 4 exposed cases distributed across 4 different types of SSRIs.  Examination 
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of the exposed case list showed that no cases were co-exposed to lithium. Although the 
strongest evidence for severe CHD types was for TOF and Ebstein’s anomaly, other 
subgroups either showed non-significant raised odds ratios (e.g. Atrioventricular septal defect 
with OR 2.08) or odds ratios closer to 1 but with wide confidence intervals. 
 
The association between SSRIs and septal defects was of borderline significance (Table 2). 
Odds ratios were generally higher for the septal defect subtype ASD (OR 1.71, 95%CI 1.09-
2.68, Table 2) than VSD, except for a VSD-paroxetine association (OR 1.90, 95%CI 1.04-
3.48, Table 2).  Among the 25 SSRI exposed ASD cases, 7 were in neonatal intensive units, 5 
were not and there is no information on the remaining 13 infants.  
 
Non-CHD signals 
There were 121 SSRI exposed babies with anomalies belonging to the 15 “signal” subgroups 
(Table 3).  For five of these subgroups, a statistically significant association was found with 
SSRI combined, or a specific SSRI type.  Exposure to SSRI was associated with increased 
odds of ano-rectal atresia and stenosis (OR 2.46, 95% CI 1.06-5.68, Table 3), but there were 
no exposures to sertraline, the origin of the signal (Table 3).  
 
Gastroschisis was associated with SSRI exposure (OR 2.42, 95% CI 1.10-5.29, Table 3), but 
was associated with other SSRI than paroxetine (Table 3).  
 
Renal dysplasia was associated with SSRI exposure (OR 3.01, 95% CI 1.61-5.61, Table 3), 
particularly fluoxetine (OR 5.76, 95% CI 2.54-13.08). 
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A significant association was found between hypospadias and citalopram (OR 3.21, 95% CI 
1.56-6.60, Table 3), while a non-significant modestly elevated OR of 1.34 (95% CI 0.58-
3.09) was found with paroxetine (Table 3).  
 
Clubfoot was associated with SSRI exposure (OR 2.41, 95% CI 1.59-3.65), particularly with 
paroxetine, sertraline and escitalopram where point estimates were close to or above 3. 
 
The OR for SSRI and craniosynostosis was of borderline statistical significance (OR 2.48, 
95% CI 0.99-6.22). Odds ratios close to one were found for neural tube defects, anencephaly, 
and eye, ear/face/neck, respiratory system defects, digestive system defects, and limb 
reduction defects (Table 3). There were less than 3 exposed cases of omphalocele which was 
not analysed separately. 
 
Subgroups included within the controls 
There were 99 SSRI exposed controls. Eleven EUROCAT subgroups had at least 3 SSRI 
exposed registrations and were analysed in comparison with all other controls combined. A 
statistically significant association was observed for SSRI and microcephaly (OR 4.15, 95% 
CI 1.60-10.78) with 5 cases distributed across 4 SSRI types (online appendix).  
 
Sensitivity analyses in which women with missing/unknown drug exposure were classified 
with the unexposed group yielded comparable odds ratios to those reported in the main 
analysis. We did not formally take into account multiple pregnancies per woman in the 
statistical analysis. However, we looked for twin and sibling pairs among the SSRI exposed. 
We found three sets of sibling/twin pairs whose mothers were exposed to SSRI. One set of 
twins had very different congenital anomalies (one non-severe cardiac, one genital), one set 
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of siblings born 10 years apart and exposed to different SSRI both had isolated congenital hip 
dislocation and one sibling pair born one year apart with the same exposure, both had CHD 
anomalies one of which was a severe CHD. Taking siblings into account therefore does not 




This is the first study to have systematically examined the full range of congenital anomalies 
in a large population. We found a statistically significant association between SSRIs as a 
class and CHD overall supporting previous reports of this association [22-37, 46-47, 68]. We 
have been able to show in addition that the association is stronger for severe CHD and, 
therefore, is unlikely to be explained as neonatal examination bias or more frequent 
echocardiograms or other screening/diagnostic procedures for SSRI exposed infants [48, 57-
58]. We have also shown that the association is not specific to any one SSRI type, although 
the power of the study to estimate differences between the effects associated with specific 
SSRIs was limited. This suggests switching from one specific SSRI to another before or in 
pregnancy is not an effective strategy to reduce the risk of CHD. Our finding of non-
specificity by SSRI type is compatible with the mechanism of teratogenic action being one 
that is common to all SSRIs and is also compatible with confounding by depression as 
indication or other associated factors/exposures.  
 
Recent studies have suggested that the association between SSRI and CHD may be explained 
by confounding [23, 33, 59]. A Danish healthcare database study of livebirths found a higher 
risk of CHD both among women exposed to SSRI in the first trimester, and those who paused 
SSRI use during pregnancy, suggesting confounding by underlying depression or factors 
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associated with depression [33]. A British healthcare database study of livebirths found a 
small excess risk of CHD (14%) with SSRI exposure, and a similarly small excess risk (10%) 
for women with unmedicated depression, and for individual SSRIs found a significantly 
elevated risk only for paroxetine when compared to unmedicated depression [23]. A US 
health insurance database study found that in an analysis restricted to women with a diagnosis 
of depression, controlling for co-exposures to other medications attenuated the CHD risks 
[59]. In our study we did not have full information on depression diagnosis, but we excluded 
women with diabetes/insulin or antiepileptic exposures where the main risk of confounding 
lies and, since the numbers of exposed cases are very small for statistical adjustment for 
confounding by co-medication, we examined case lists for evidence of potential confounding 
by co-medications and found none. We also used validated registry CA diagnoses, including 
TOPFA, rather than relying on the problematic recording of CA in healthcare databases [71]. 
Further investigation of the hypothesis that the causal association is with the underlying 
depression is necessary, taking into account the specificity we find in relation to types of 
CHD and other CA.  Moreover, the evidence that maternal depression increases congenital 
anomaly risk is lacking [6], although there are known associations with stress [72], and this 
requires further research.  
 
We found previously unreported associations between SSRI and Tetralogy of Fallot (OR 
3.16, 95% CI 1.52-6.58) and Ebstein’s anomaly (OR 8.23, 95% CI 2.92-23.16). The finding 
relating to Ebstein’s anomaly is of particular interest given that it has previously been 
reported to be associated with the antipsychotic drug lithium [73] which has led to avoidance 
of lithium use in pregnancy, although the evidence remains controversial [74]. None of the 
SSRI exposed Ebstein’s anomaly cases in our data also had lithium exposure and the SSRI 
association appears to be an independent finding.    
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Our findings support an association between SSRIs and ASD, but we found no evidence that 
this was specific to paroxetine as previously reported [32-33] and we did find some evidence 
that exposed cases of ASD tended to have been cared for in neonatal units and thus biased 
ascertainment of ASD is possible. We found a previously unreported association between 
paroxetine and VSD, which did appear to be specific only to paroxetine. 
 
Among 15 non-CHD signals in the literature, 5 were supported by statistically significant 
associations with odds ratios above 2 in our data (ano-rectal atresia and stenosis, 
gastroschisis, renal dysplasia, clubfoot and hypospadias). Craniosynostosis was also of 
borderline significance. Except for hypospadias, these associations were not confined to any 
one SSRI, and often not the SSRI type of the original signal [24, 29, 32, 34-35]. 
Gastroschisis, is strongly associated with socio-economic deprivation and lifestyle exposures, 
including smoking and recreational drugs [75], and confounding or cumulative or interacting 
exposure effects should also be considered as an explanation for its association with SSRI 
use. For other anomalies, the evidence concerning factors such obesity [76], smoking [77], 
and alcohol use [78] would suggest that confounding would be unlikely to be strong enough 
to explain odds ratios above 2.   
 
For the other signal subgroups (neural tube defects/anencephaly, eye, ear/face/neck, 
respiratory system, digestive system, omphalocele, limb reduction) our data do not support 
associations with SSRI, but generally wide confidence intervals cannot exclude moderate 
associations.  Folic acid could have been an unmeasured confounder in our analyses - the 
absence of an association between SSRI and neural tube defects (the congenital anomaly 
most strongly associated with folic acid), suggests that either SSRI users are as likely to use 
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folic acid as other mothers, or that SSRI users take more folic acid but folic acid protects 
against the teratogenic effects of SSRI.   
 
The finding in the exploratory analysis of a significant association with microcephaly is of 
interest given the wide range of teratogenic exposures associated with microcephaly [79] but 
confounding and the likelihood of spurious chance associations due to multiple testing mean 
that this should be very cautiously interpreted until confirmed by other studies.  
 
Strengths and limitations 
This study has several strengths. It used data from a large population-based congenital 
anomaly surveillance system covering approximately 2 million births in 12 European 
countries providing the opportunity to study some rare CHD types and other congenital 
anomalies. Importantly, the database has information on TOPFA following prenatal diagnosis 
which constituted about 5.9% of all (non-genetic) registrations, a much higher proportion for 
more severe CAs. Inclusion of TOPFA is particularly important since uptake of prenatal 
diagnosis and TOPFA may be associated with depression, SSRI use or socioeconomic 
correlates. For most of the registries, exposure data were recorded prospectively before 
outcome was known eliminating the possibility of recall bias, but in addition the use of 
malformed controls meant that there was little opportunity for recall bias.  
 
The main limitation of the study relates to exposure classification. There was undoubtedly 
underascertainment of antidepressant use, as shown by the relatively low exposure prevalence 
of 0.8% overall, when compared to population-based estimates among pregnant women [9, 
12-15, 79]. SSRI exposure is difficult to ascertain accurately, and even comparisons between 
research birth cohorts and prescription databases have shown considerable unexplained 
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discrepancies [51, 80].  One quarter of registrations had missing exposure information. While 
there is no reason to believe this exposure misclassification was differential across cases and 
controls and thus would lead to bias, the low exposure prevalence did decrease the statistical 
power of the study. There was no information on dosage or length of exposure to SSRIs – 
Berard et al [37] suggested that the teratogenic effect of paroxetine may be limited to higher 
doses (25mg/day). We assumed, as is customary, that the relevant exposure window was the 
first trimester (as these are the available EUROCAT data) but this window is wider than the 
sensitive period for many congenital anomalies, some congenital anomalies may occur after 
later exposures [81]. On the other hand, some of the exposures recorded do not specify timing 
precisely and may be misattributed to the first trimester, although we verified timing for 
anomalies where significant associations were found. In general, misclassification of 
exposure is likely to have led to underestimation of odds ratios. 
 
Use of malformed controls could lead to underestimation of the odds ratio if the SSRIs under 
study also caused malformations that are included in the controls. However, by design, we 
excluded all known non-CHD “signals” from the control group and an exploratory analysis 
carried out on the control group found only one anomaly subgroup (microcephaly) to be 
disproportionately represented among the SSRI exposed. We excluded chromosomal 
syndromes from both cases and controls. Further research could examine whether a fetus with 
a chromosomal syndrome has a greater sensitivity to the teratogenic effect of SSRIs, but our 
study did not have the statistical power to do this. 
 
Multiple comparisons were carried out and some of the significant associations might be due 
to chance, although we tried to minimise this problem by clear specification of prior 
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hypotheses. Data were unavailable on possible confounding co-exposures as already 
discussed. 
 
Implications for Practice 
Our data cannot resolve whether the association between SSRI use and congenital anomalies 
is a causal one. We have however been able to show the range of congenital anomalies 
associated with SSRI use includes severe CHD and also goes beyond CHD, we have 
estimated the strength of association for each anomaly, and shown that the risks are found 
across a range of specific SSRI types. In a population of 100,000 pregnant women, of whom 
4% [14] take SSRIs during the first trimester (4,000 women), we can estimate from our data, 
using EUROCAT congenital anomaly prevalence estimates, that an extra 28 cases would be 
born with major congenital anomalies to these women, of which under half would be cardiac 
defects. On a population basis, this strongly reinforces the importance of population measures 
to prevent depressive illness prior to and during pregnancy, to make readily available the 
choice of non-pharmacological treatments, and to prioritise further research on both 
depression and antidepressants. On an individual basis, the additional risk of congenital 
anomaly (approximately 0.5%) is very low.  These low estimated risks, which should 
however be considered together with adverse effects of later pregnancy exposures such as 
poor neonatal adaptation syndrome, newborn pulmonary hypertension and possible 
neurodevelopmental effects [6], must be balanced for each individual woman against the 
benefits of choosing SSRI treatment, benefits which can be vital for both mother and baby in 
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Table 1:  
Registry, population (births), number of Congenital Anomaly (CA) registrations, and number and % 
SSRI exposure 
 
Registry Birth Years Births CA SSRI (N) SSRI (%) 
Antwerp (Belgium)M 2000-2004 61,585 1,776 5 0.30 
Basque Country (Spain)M 2005-2009 103,040 1,188 8 0.70 
Cork & Kerry (Ireland)M 1996-2004 71,625 1,086 10 0.90 
MaltaM 1995-1999 23,368 615 1^ 0.20 
Northern NetherlandsM,I,P 1995-2009 288,971 5,217 53 1.00 
NorwayM 2000-2009 590,747 15,347 82 0.50 
Odense (Denmark)M 2000-2009 53,491 932 21 2.30 
Paris (France)M 2000-2009 278,435 5,104 15 0.30 
Saxony-Anhalt 
(Germany)M,I 2005-2009 86,662 1,605 7 0.40 
Tuscany (Italy)I 2005-2009 152,137 778 7 0.90 
Vaud (Switzerland)M 2000-2009 73,522 1,657 6 0.40 
Wales (UK)M 1998-2009 394,394 7,678 113 1.50 
TOTAL   2,177,977 42,983 328 0.76 
^Malta fulfilled inclusion criteria of 5 exposed CA registrations before specific exclusions were made. 
MMedication ascertainment from prospective maternal medical/midwifery notes 
I Information on medication exposure taken from or confirmed through maternal interviews after birth 
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Table 2: Number (N) and Odds Ratios (OR) of maternal exposure to SSRIs, combined and by SSRI type, comparing CHD subgroups with controls, 12 
EUROCAT registries 1995-2009  
CA SSRI Fluoxetine Paroxetine Citalopram Sertraline Escitalopram 
 N N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 












Severe CHD 2935 28 1.56  
(1.02-2.39) 
8 1.46  
(0.66-3.23) 
6 1.08  
(0.44-2.63) 




2 1.65  
(0.35-7.81) 
     Transposition Great Vessels 615 3 0.79  
(0.25-2.52) 
0 - 1 - 0 - 1 - 1 - 
     Tetralogy of Fallot 428 8 3.16  
(1.52-6.58) 
4 5.03  
(1.73-14.58) 
0 - 2 4.41  
(1.02-19.15) 




     Atrioventricular Septal Defect 290 4 2.08  
(0.76-5.73) 
2 - 1 - 0 - 1 - 0 - 
     Ebstein's anomaly 93 4 8.23  
(2.92-23.16) 
0 - 1 6.43  
(0.85-48.54) 
1 12.36  
(1.61-95.15) 
1 16.42  
(2.10-128.38) 
1 34.19  
(4.09-286.04) 
     Hypoplastic Left Heart 398 3 1.22  
(0.38-3.88) 
1 - 1 - 1 - 0 - 0 - 
     Coarctation of aorta       570 4 1.12  
(0.41-3.07) 
0 - 2 - 0 - 2 - 0 - 
Septal defects 8131 64 1.36  
(0.99-1.87) 
16 1.23  
(0.66-2.29) 
23 1.92  
(1.09-3.37) 
9 0.88  
(0.40-1.94) 
9 1.33  
(0.57-3.09) 
7 1.62  
(0.60-4.36) 
     Atrial Septal Defect (ASD) 2691 25 1.71  
(1.09-2.68) 
6 1.67  
(0.68-4.11) 
5 1.38  
(0.52-3.69) 
4 1.28  
(0.43-3.75) 
5 2.02  
(0.71-5.71) 
5 3.31  
(1.11-9.90) 
     ASD without Severe  CHD 2378 20 1.54  
(0.94-2.52) 
5 1.58  
(0.60-4.19) 
5 1.65  
(0.62-4.42) 
3 1.07  
(0.31-3.61) 
2 - 5 3.62  
(1.21-10.83) 
     Ventricular Septal Defect 
(VSD) 
6167 41 1.12  
(0.77-1.61) 
10 0.97  
(0.47-2.02) 
18 1.90  
(1.04-3.48) 
5 0.63  
(0.24-1.70) 
6 1.15  
(0.44-3.01) 
2 - 
     VSD without Severe CHD 5511 36 1.12  
(0.76-1.65) 
10 1.12  
(0.54-2.34) 
17 2.12  
(1.15-3.92) 
5 0.71  
(0.26-1.90) 
4 0.84  
(0.27-2.57) 
0 - 
Pulmonary Valve Stenosis 772 7 1.30  
(0.60-2.83) 
3 1.76  
(0.53-5.89) 
1 - 2 - 1 - 0 - 
*ORs were adjusted for registry.  
OR italicised are reported even though the number of exposed cases was less than 3 to help assess specificity of effect. 
The EUROCAT severe CHD subgroups truncus arteriosus, single ventricle, tricuspid atresia, total anomalous pulmonary venous return, hypoplastic right heart, aortic stenosis, and pulmonary atresia have less than 3 SSRI exposed 
cases each and therefore not reported separately, but included in totals 
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Table 3: Number (N) and Odds Ratios (OR) of maternal exposure to SSRIs, combined and by SSRI type, comparing non-CHD signal subgroups with controls, 12 EUROCAT 
registries 1995-2009  
CA SSRI Fluoxetine Paroxetine Citalopram Sertraline Escitalopram 
 N N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
N Adj* OR 
(95% CI) 
Neural tubes,p,c   1322 8 0.90  
(0.43-1.88) 
3 0.99  
(0.30-3.29) 
0 - 2 - 1 - 1 - 
     Anencephalys 473 3 0.89  
(0.28-2.84) 
2 - 0 - 1 - 0 - 0 - 
Eyep 828 7 1.13  
(0.52-2.47) 
1 - 3 1.37  
(0.41-4.59) 
2 - 0 - 1 - 
Ear, face & neckf 746 3 0.71  
(0.22-2.25) 
2 - 0 - 0 - 0 - 1 - 
Respiratory systems* 983 7 1.08  
(0.50-2.35) 
1 - 0 - 2 - 2 - 0 - 
Digestive systemf 2739 19 1.13  
(0.69-1.87) 
5 0.96  
(0.36-2.51) 
7 1.25  
(0.54-2.90) 
2 - 1 - 2 - 




2 2.82  
(0.66-11.96) 
1 2.19  
(0.29-16.63) 
0 - 1 6.02  
(0.73-49.62) 
Gastroschisisp 413 7 2.42  
(1.10-5.29) 
2 2.28  
(0.53-9.82) 
0 - 3 5.10  
(1.46-17.75) 
1 2.69  
(0.34-21.05) 
1 5.05  
(0.62-40.90) 
Renal dysplasias 618 12 3.01 
 (1.61-5.61) 
8 5.76  
(2.54-13.08) 
2 1.62  
(0.38-6.95) 
1 1.40  
(0.18-10.86) 
0 - 0 - 
Hypospadiasp 3041 25 1.34  
(0.86-2.09) 
2 - 7 1.34  
(0.58-3.09) 
12 3.21  
(1.56-6.60) 
2 - 2 - 
Limb reductions* 784 6 1.15  
(0.50-2.65) 
2 - 3 1.86  
(0.56-6.17) 
0 - 0 - 1 - 
Clubfoots,p 1992 30 2.41  
(1.59-3.65) 
6 1.65  
(0.68-4.03) 
10 2.99  
(1.44-6.21) 
5 1.91  
(0.71-5.11) 
5 3.05  
(1.09-8.52) 
4 3.88  
(1.19-12.69) 
Craniosynostosiss 307 5 2.48  
(0.99-6.22) 
2 - 1 - 1 - 1 - 0 - 
Signal source s=SSRI, f=Fluoxetine, p=Paroxetine, c=Citalopram, s*=Sertraline. 
*ORs were adjusted for registry.  
Omphalocele and lower limb reduction anomaly  have 1 SSRI exposed case each and therefore not separately reported. 
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